Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $89

Benzinga Newsdesk www.benzinga.com Negative 94.5%

Neg 94.5% Neu 0% Pos 0%

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $94 to $89.